Poor
Not Aligned
Patient Risk:
Moderate
Summary
Only the asthma maintenance vs not-for-acute-symptoms claims are supported by the provided label excerpt. The remaining claims are primarily about prescribing requirements, purchasing/availability, pricing, pharmacy practices, and risks from unlicensed sellers, which are not addressed in the supplied FDA-approved label excerpts and therefore cannot be confirmed as on-label. These unsupported claims materially reduce alignment.
Category Scores
Accurate Statements
Arnuity Ellipta is a prescription inhaler.
Not supported in the provided label excerpts (no prescription/OTC language included).
Arnuity Ellipta is a branded form of fluticasone furoate.
Not supported in the provided label excerpts (no explicit 'branded form' wording included; only active ingredient and product name provided).
The label indicates ARNUITY ELLIPTA is indicated for maintenance treatment of asthma and NOT indicated for relief of acute bronchospasm/acute symptoms; extra doses should not be used for that purpose; acute symptoms should be treated with an inhaled short-acting beta2-agonist (e.g., albuterol).
1 INDICATIONS AND USAGE (NOT indicated for relief of acute bronchospasm); 5.2 Acute Asthma Episodes (extra doses should not be used for acute symptoms; treat with inhaled short-acting beta2-agonist); 17 Patient Counseling (Not for Acute Symptoms; instruct use of short-acting beta2-agonist such as albuterol).
Unsupported Statements
To buy Arnuity Ellipta, a valid prescription from a clinician is generally required.
The provided label excerpts do not address how it must be obtained (prescription requirement/retail access).
Arnuity Ellipta can be purchased through a pharmacy or a pharmacy’s online ordering service.
The provided label excerpts do not address purchasing channels.
Availability of Arnuity Ellipta can vary by location.
The provided label excerpts do not address distribution/availability by geography.
Availability of Arnuity Ellipta can vary depending on whether buying the brand or a generic version.
The provided label excerpts do not discuss generics or brand vs generic availability.
Arnuity Ellipta pricing often depends on insurance status.
The provided label excerpts do not discuss pricing factors.
Arnuity Ellipta pricing often depends on the pharmacy.
The provided label excerpts do not discuss pricing.
Arnuity Ellipta pricing often depends on whether an insurance plan covers the brand.
The provided label excerpts do not discuss insurance coverage or pricing.
Checking a pharmacy’s cash price can be used to reduce out-of-pocket cost.
The provided label excerpts do not provide any guidance about cost-minimization strategies.
Whether insurance requires prior authorization can affect Arnuity Ellipta out-of-pocket cost.
The provided label excerpts do not discuss prior authorization or out-of-pocket cost.
Insurance may prefer a different inhaled steroid over Arnuity Ellipta.
The provided label excerpts do not discuss payer formulary preferences.
Generic alternatives for Arnuity Ellipta may be available in some markets.
The provided label excerpts do not discuss generic availability.
In most places, Arnuity Ellipta is not sold legally without a prescription.
The provided label excerpts do not address legal sale conditions or jurisdictional rules.
Buying Arnuity Ellipta from unlicensed sellers can be risky because it may result in receiving counterfeit medication.
The provided label excerpts do not mention counterfeit risk.
Buying Arnuity Ellipta from unlicensed sellers can be risky because it may result in receiving expired medication.
The provided label excerpts do not mention risk of expired medication from unlicensed sellers.
Arnuity Ellipta is supplied in different strength inhalers.
Partially supported: label states inhalation powder contains fluticasone furoate 50 mcg, 100 mcg, or 200 mcg. However, the specific framing as 'different strength inhalers' is not explicitly stated in the exact phrase; still likely consistent with 3 dosage forms and strengths, but not all label excerpt is captured as 'inhalers.'
The exact Arnuity Ellipta inhaler strength needed depends on the prescription.
The provided label excerpts do state recommended dosages depend on patient age and prior therapy (2.2), but this specific statement about dependence on 'the prescription' is not explicitly described.
The exact Arnuity Ellipta strength needed depends on the prescribed dose.
The provided label excerpts do state recommended starting dosage and maximum recommended dosage by strength, but the wording 'depends on the prescribed dose' is not directly stated.
The exact Arnuity Ellipta strength needed depends on whether it is meant for daily maintenance.
The label describes maintenance treatment but does not state that strength selection depends on being 'meant for daily maintenance' (strength selection is discussed in terms of age/prior therapy/response).
When ordering Arnuity Ellipta, matching the label exactly to the prescription is necessary to avoid getting the wrong strength.
The label excerpts do not provide ordering/pharmacy counsel about matching label to prescription to avoid wrong strength.
Don’t assume all fluticasone inhalers are the same strength or product as Arnuity Ellipta.
The provided label excerpts do not contain this comparative product guidance.
When ordering Arnuity Ellipta, double-check the exact product name and strength.
The provided label excerpts do not contain ordering/pharmacy double-check instructions.
When ordering Arnuity Ellipta, double-check the quantity (device count).
The provided label excerpts do not mention device count/quantity checking.
When ordering Arnuity Ellipta, double-check whether the product is the brand or an equivalent.
The provided label excerpts do not discuss brand vs equivalent substitution at ordering.
When ordering Arnuity Ellipta, double-check the expiration date.
The provided label excerpts do not provide expiration-date checking instructions.
When ordering Arnuity Ellipta, double-check pharmacy legitimacy.
The provided label excerpts do not provide guidance about pharmacy legitimacy.
Contradictions
Important Omissions
No dosing/administration details were included in the user-provided set of claims beyond non-label ordering/pharmacy advice; the label excerpt specifies administration timing (once daily, not more than once every 24 hours), mouth rinsing after inhalation, and maximum benefit timing (may take up to 2 weeks or longer).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several claims provide logistical purchasing/ordering and risk-related statements not supported by the provided FDA label excerpts. While they are not directly contradicted by the label, the lack of label support limits confidence and could distract from label-based safe use (maintenance vs acute symptoms) and label-specific administration guidance.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most claims (prescription requirement, purchasing/availability, pricing, prior authorization, unlicensed seller risks, and ordering double-check instructions) are not supported by the supplied FDA label excerpts.
Suggested Improvement
Limit claims to label-supported content from the provided excerpts (maintenance indication; not for acute bronchospasm; extra doses not for acute symptom relief; treat acute symptoms with inhaled short-acting beta2-agonist; dosing/strength ranges by age and recommended administration instructions). Remove or rephrase unsupported retail/pricing/ordering and counterfeit/expiration assertions unless included in the provided label.